AngioDynamics Reports Strong Q2 Results, Raises FY26 Guidance, and Secures Key Regulatory Approvals

summarizeSummary

AngioDynamics reported strong fiscal Q2 2026 financial results, driven by double-digit Med Tech growth and improved profitability, leading to increased full-year guidance. The company also announced multiple FDA regulatory milestones and a planned CEO retirement for fiscal 2027.

check_boxKey Events

• Strong Q2 Financial Performance

  Net sales increased 8.8% year-over-year to $79.4 million, with the Med Tech segment growing 13.0%. Adjusted EBITDA significantly improved to $5.9 million, up from $3.1 million in the prior-year quarter, and the company achieved an adjusted loss per share of $0.00.

• Raised Full-Year FY26 Guidance

  AngioDynamics increased its fiscal year 2026 net sales guidance to a range of $312-$314 million (from $308-$313 million) and raised its adjusted EBITDA guidance to $8.0-$10.0 million (from $6.0-$10.0 million), reflecting strong operational execution.

• Multiple Regulatory Milestones Achieved

  The company received FDA IDE approvals for its APEX-Return and PAVE clinical studies, and 510(k) clearance for a modified AlphaVac F18 85 System, enhancing its mechanical thrombectomy portfolio and expanding indications for use.

• Planned CEO Retirement Announced

  President and CEO Jim Clemmer informed the Board of his intention to retire during fiscal year 2027 upon the appointment of a successor, with a comprehensive search initiated to ensure a smooth leadership transition.

auto_awesomeAnalysis

AngioDynamics delivered a strong fiscal second quarter, exceeding expectations with robust Med Tech segment growth and significantly improved adjusted EBITDA. The company's decision to raise its full-year net sales and adjusted EBITDA guidance signals confidence in its continued operational momentum and strategic transformation. Multiple FDA approvals and clearances for its mechanical thrombectomy portfolio further strengthen its product pipeline and market position. While the planned CEO retirement introduces a future leadership transition, it is framed as an amicable and managed process, unlikely to overshadow the immediate positive financial and product developments. The stock trading near its 52-week high reflects positive market sentiment aligned with these developments.